Showing 3631-3640 of 20433 results for "".
- 4% Tetrasodium EDTA Lowers CVAD Complications in ICU Trialhttps://reachmd.com/news/tetrasodium-edta-cvad-complications/2487397/Key Takeaways The primary composite outcome occurred less often during t-EDTA periods than during control periods. In prespecified analyses of the primary outcome components, only catheter occlusion requiring alteplase use showed a significant between-
- Postoperative Nivolumab Does Not Improve DFS in Resected NSCLChttps://reachmd.com/news/postoperative-nivolumab-does-not-improve-dfs-in-resected-nsclc/2487358/Key Takeaways Adjuvant nivolumab was not associated with a significant disease-free survival benefit compared with observation in patients with resected NSCLC who completed standard adjuvant therapy. No significant disease-free survival benefit was obs
- COLOR III Short-Term Outcomes: taTME vs Laparoscopic TMEhttps://reachmd.com/news/color-iii-tatme-laparoscopic-tme/2487343/Key Takeaways taTME was associated with lower conversion than laparoscopic TME in this short-term comparison. 90-day morbidity, anastomotic leakage, and macroscopically complete resection appeared similar between groups. In the
- Baseline Imaging in ESCAPE-MeVO Linked To 90-Day Outcomeshttps://reachmd.com/news/baseline-imaging-in-escape-mevo-linked-to-90-day-outcomes/2487285/Key Takeaways Baseline head CT, CTA, and CT perfusion findings were reviewed in a central blinded core laboratory analysis of ESCAPE-MeVO participants. CTA collateral status was associated with 90-day modified Rankin Scale outcome, and the abstract des
- Integrase Versus Protease Inhibitors In Advanced HIV Diseasehttps://reachmd.com/news/integrase-versus-protease-inhibitors-in-advanced-hiv-disease/2487284/Key Takeaways Across planned analyses, the bictegravir-based regimen matched the comparator on the primary composite endpoint and met the trial's noninferiority threshold. Grade 2 or higher drug-related adverse events were less frequent with bictegravi
- Budesonide Glycopyrronium Formoterol Improved Lung Function in Phase 3 Asthma Trialshttps://reachmd.com/news/budesonide-glycopyrronium-formoterol-improved-lung-function-in-phase-3-asthma-trials/2487270/Key Takeaways Multiplicity-adjusted primary lung-function endpoints were met in both studies, and lung function favored budesonide-glycopyrronium-formoterol 320/28.8/10 mcg across comparisons. Pooled severe exacerbation rates were lower versus the comb
- Guselkumab Shows Week 24 Efficacy After TNF Inhibitor Failure in PsAhttps://reachmd.com/news/guselkumab-shows-week-24-efficacy-after-tnf-inhibitor-failure-in-psa/2487212/Key Takeaways Both guselkumab schedules were associated with higher week 24 responses than placebo across the reported efficacy endpoints. Week 24 efficacy appeared similar between the every-4-week and every-8-week guselkumab regimens. Adverse
- CBT After Esketamine in Major Depression and Suicidal Ideationhttps://reachmd.com/news/cbt-after-esketamine-in-major-depression-and-suicidal-ideation/2487211/Key Takeaways The randomized comparison met feasibility criteria, reaching 80% of targeted enrollment and 70% retention through the study endpoint. Over 18 weeks, several clinician- and patient-rated measures favored the CBT group over treatment as usu
- BCG Plus Mitomycin Fails to Improve DFS in ANZUP 1301https://reachmd.com/news/bcg-mitomycin-dfs-anzup-1301/2487173/Key Takeaways BCG plus mitomycin did not show disease-free survival superiority over BCG alone in this randomized phase 3 trial. Recurrence and progression events were numerically lower in the combination arm, and other secondary counts were reported f
- CASCARA Phase II Tests Cabazitaxel-Carboplatin-Abiraterone In mCSPChttps://reachmd.com/news/cascara-phase-ii-tests-cabazitaxel-carboplatin-abiraterone-in-mcspc/2487152/Key Takeaways Twelve-month PSA progression-free survival was 84.6%, and 12-month overall survival was 94.8%. Complete PSA and objective responses were reported, while HRR-mutated patients had numerically fewer complete PSA responses and shorter progres